SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published articles

17 Jan 2013 07:00

RNS Number : 7246V
Tristel PLC
17 January 2013
 



Tristel plc

("Tristel")

 

Peer-reviewed published articles supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of two articles in peer-reviewed journals that describe the benefits of Tristel products.

 

The first is titled "Guidelines for Reprocessing Non-lumened Heat-Sensitive Ear/Nose/Throat Endoscopes" and has been published in The Laryngoscope, the journal of The American Laryngological, Rhinological and Otological Society (Laryngoscope , 122:1708-1718, 2012). The article proposes the standardisation of disinfection procedures for ENT endoscopes and reviews a number of technologies including Tristel's Wipes System, Stella decontamination system and Shine automated washer-disinfector. 

 

The second publication is of a study undertaken in the Prince of Wales Hospital, Hong Kong, and is titled "Transvaginal ultrasound probe contamination by the human papillomavirus in the emergency department" (Emergency Medicine Journal, July 2012). The study revealed the prevalence of human papillomavirus (HPV) on the ultrasound equipment used routinely in the hospital and indicated that existing disinfection methods were inappropriate. The hospital has adopted the Tristel Wipes System to improve its decontamination process. 

 

Tristel CEO, Paul Swinney, commented: "We believe the Wipes System is now gaining recognition as the "gold standard" for ENT endoscopes in countries where it has been approved for use, which include all those in the European Community, Australia and many countries in the Far East. Whilst we have not attempted to register the Wipes System in the United States, its inclusion in The Laryngoscope review of decontamination methodologies, which is the most widely read journal for ENT worldwide, is a significant benefit to the marketing of our product.

 

"A second area in the hospital where the Wipes System is achieving rapid uptake in the United Kingdom and Australia is ultrasound. The Prince of Wales study joins a growing body of scientific evidence that existing methods of disinfecting intra-vaginal and rectal ultrasound probes are inadequate. The Wipes System is considered to be a more effective method of disinfection. In terms of patient procedures, and therefore disinfectant use, ultrasound is as large a market as digestive and respiratory medicine where almost all the attention of the infection control market has been focused for the past twenty years. Our product strategy of focusing on the smaller non-lumened instruments used in ENT and ultrasound positions us well for continued growth in this area."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFUFMMFDSEDF
Date   Source Headline
13th Oct 20168:33 amRNSIssue of Equity
12th Oct 20168:12 amRNSStudy shows Tristel Wipes System benefits
11th Oct 20167:00 amRNSStudy shows Tristel Wipes System benefits
20th Sep 20167:00 amRNSNotice of Results
19th Sep 20169:24 amRNSIssue of Equity
12th Sep 20167:00 amRNSRegulatory approval in Australia for surface range
19th Aug 20164:30 pmRNSDirector/PDMR Shareholding
19th Aug 20161:30 pmRNSIssue of Equity
21st Jul 20163:26 pmRNSDirector Dealing
21st Jul 20167:00 amRNSTrading update, Special dividend & Acquisition
25th May 20167:00 amRNSShareholder Open Day & Notice of Trading Update
29th Apr 201611:06 amRNSDirector Dealing
26th Apr 201610:06 amRNSDirector Dealing
15th Mar 20167:00 amRNSDirector Dealing
11th Mar 20167:00 amRNSDirector Dealing
10th Mar 20167:00 amRNSDirector Dealing
2nd Mar 20165:13 pmRNSDirector Dealing
2nd Mar 20169:46 amRNSDirector Dealing
29th Feb 20167:00 amRNSDirector Dealing
26th Feb 20169:43 amRNSDirectors Dealings
24th Feb 20167:00 amRNSHalf Yearly Report
25th Jan 20167:00 amRNSNotice of Results
13th Jan 20164:53 pmRNSIssue of Equity
5th Jan 20167:00 amRNSTransition of German branch to subsidiary status
15th Dec 20151:43 pmRNSDirectors Dealings
15th Dec 201512:18 pmRNSResult of AGM
15th Dec 20157:00 amRNSAGM Statement
2nd Dec 201511:37 amRNSIssue of Equity
1st Dec 201511:06 amRNSPosting of Annual Report & Notice of AGM
1st Dec 201511:05 amRNSFrench study shows superiority of Tristel Wipes
2nd Nov 20153:42 pmRNSIssue of Equity
22nd Oct 20154:02 pmRNSIssue of Equity
15th Oct 20159:50 amRNSIssue of Equity/Director Dealing
12th Oct 20157:00 amRNSFinal Results
5th Oct 20157:00 amRNSInvestor results briefing - Change of venue
1st Oct 20157:00 amRNSAppointment of Non-Executive Director
25th Sep 20151:52 pmRNSIssue of Equity
18th Sep 20157:00 amRNSNotice of Results
18th Aug 201510:14 amRNSIssue of Equity
17th Aug 20151:07 pmRNSDirector Share Transfer
6th Aug 201511:01 amRNSIssue of Equity
4th Aug 201511:57 amRNSDirectors dealing/grant of options
20th Jul 20154:25 pmRNSIssue of Equity
30th Jun 20154:59 pmRNSIssue of Equity
24th Jun 20154:08 pmRNSIssue of Equity
23rd Jun 20153:15 pmRNSIssue of Equity
18th Jun 20159:00 amRNSDirector Dealing/Issue of Equity
18th Jun 20157:00 amRNSSpecial Dividend and notice of results
9th Jun 20151:44 pmRNSTristel welcomes Cardiff University wipes study
3rd Jun 201512:20 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.